Introduction
Guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, is efficacious in participants (pts) with Crohn’s disease (CD) after intravenous (IV) or subcutaneous (SC) induction and SC maintenance. Previously, we reported that the average serum concentrations of GUS IV or SC induction were similar through week (W) 12.1 Here, we evaluated the pharmacokinetics (PK) and exposure-response (E-R) of GUS SC maintenance regimens (100 mg every 8 weeks [q8w] or 200 mg every 4 weeks [q4w]).
Aims & Methods
The phase 2 GALAXI 1, phase 3 GALAXI 2 and 3, and phase 3 GRAVITI studies had treat-through designs and the same SC maintenance regimens (100 mg q8w or 200 mg q4w) in pts with CD. Population PK modeling was performed on pooled GALAXI (through W48) and GRAVITI (through W24) PK data. E-R efficacy relationships at W48 were explored descriptively and via modeling. Associations between exposure and safety and covariate impacts on E-R were also investigated. Analyzed pts had received ≥1 GUS dose and had a Simple Endoscopic Score for CD (SES-CD) ≥6 (≥4 for pts with isolated ileal CD) and ≥1 post-baseline (BL) PK value.
Results
Higher body weight, lower serum albumin, higher C-reactive protein, and inadequate response or intolerance to biologic therapies were associated with faster clearance (CL); these effects did not warrant covariate-based dose adjustment. Positive E-R trends were observed between steady-state GUS concentration and W48 efficacy (clinical remission, endoscopic response, endoscopic remission) and remained after accounting for CL or half-life. In GALAXI, clinical remission rates by trough GUS concentration quartiles (W48) were 47% for ≥0.01–≤0.816 (quartile [Q] 1), 82% for >0.816–≤2.54 (Q2), 73% for >2.54–≤7.72 (Q3), and 83% for >7.72–≤23.4 (Q4), and endoscopic response rates were 29% (Q1), 65% (Q2), 51% (Q3), and 66% (Q4). In GRAVITI, clinical remission rates were 48% (Q1), 77% (Q2), 66% (Q3), and 82% (Q4); respective endoscopic response rates were 37%, 51%, 43%, and 63%. Exposures for both GUS maintenance dose regimens were associated with substantial efficacy for most pts; 200 mg SC q4w exposures were at the plateau of the E-R curves, suggesting that maximal response is more likely with this regimen. In the PK model, BL SES-CD or clinical remission/endoscopic response status at W12 were associated with W48 clinical remission or endoscopic response outcomes (Table). Immunosuppressants did not impact GUS concentrations. No associations between concentrations and infections, serious infections, serious adverse events, or abnormal liver function tests were observed.
Model-predicted week 48 response rates for SC maintenance treatment groups, stratified by covariates
|
|---|
CI=confidence interval, q4w=every 4 weeks, q8w=every 8 weeks, SC=subcutaneous, SES-CD=Simple Endoscopic Score for Crohn’s Disease. aResponse rate was calculated based on model-predicted median Ctrough, week 48, which is 0.84 µg/mL for the 100 mg SC q8w regimen and 7.60 µg/mL for the 200 mg SC q4w regimen.
|
Response variable at week 48
| Covariates | Response rate, % (95% CI) |
Endoscopic response
| Baseline SES-CD >12 Yes Yes No No
| Endoscopic response at week 12 Yes No Yes No
| 100 mg SC q8wa 77.9 (68.0–85.4) 42.6 (31.8–54.2) 58.9 (48.0–68.9) 23.2 (16.9–30.8)
| 200 mg SC q4wa 86.8 (79.8–91.6) 58.0 (46.6–68.6) 69.2 (59.4–77.5) 32.1 (24.6–40.7)
|
Clinical remission
| Clinical remission at week 12 Yes Yes No No
| Endoscopic response at week 12 No Yes No Yes
| 100 mg SC q8wa 88.6 (83.2–92.4) 94.6 (91.1–96.7) 55.3 (46.4–63.9) 73.5 (63.6–81.5)
| 200 mg SC q4wa 92.3 (88.3–95.1) 96.8 (94.6–98.2) 65.8 (57.3–73.4) 83.1 (75.1–88.9)
|
Conclusion
Both GUS maintenance regimens were highly efficacious in pts with CD. PK modeling predicted that, in pts who were not in clinical remission or endoscopic response at W12, maximal long-term efficacy would most likely be attained with the 200 mg q4w regimen.
References
1. D’Haens, GR, et al. S1986 Guselkumab pharmacokinetics and exposure-response relationships are consistent following intravenous vs subcutaneous induction in participants with Crohn’s disease. The American Journal of Gastroenterology. 2025; 120(10S2):p S426.
Disclosure
Bruce E. Sands reports honoraria for consulting from Aclaris Therapeutics, Adaxion Therapeutics, Adiso Therapeutics, Agomab Therapeutics, Alfasigma, Alimentiv, Amgen, AnaptysBio, AstraZeneca, Attovia Therapeutics, Biolojic Design, BiomeBank, Biora Therapeutics, Boehringer-Ingelheim, Caldera Therapeutics, Cellarity, Cytoki Pharma, Disc Medicine, Eil Lilly & Company, Ensho Therapeutics, Enthera, Enveda Biosciences, Equilium, Evommune, Ferring, Fzata, Galapagos, Genentech (Roche), Genesis Therapeutics, Gilead Sciences, GlaxoSmithKline, Globalport, Ignite Biomedical, Imedex, Imhotex, Immunitas Therapeutics, Immunyx Pharma, Kallyope, Kyowa Kirin, LifeMine Therapeutics, Merck & Co., Merck Sharp & Dohme, Microba, Microbiotica, Mirador Therapeutics, Mitsubishi Tanabe Pharma, Mobius Care, Morphic Therapeutic, MRM Health, Nexus Therapeutics, Nimbus Discovery, Novartis, Numab Therapeutics, Odyssey Therapeutics, ONO Pharmaceutical, OSE Immunotherapeutics, Palisade Bio, Pioneering Medicines Explorations, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Quotient Therapeutics, Rasayana Therapeutics, Recludix Pharma, Reistone Biopharma, Sanofi, Slate Bio, Sorriso Pharmaceuticals, Spyre Therapeutics, Synlogic, Target RWE, Televant, Teva, Thetis Pharmaceuticals, SRT Therapeutics, TR1X, Trex Bio, Union Therapeutics, VectivBio, Vedanta Biosciences, Vividion Therapeutics, and Xencor; honoraria for consulting and speaking and other support from AbbVie, Abivax, Bristol Myers Squibb, Celltrion, Eli Lilly & Company, Genentech (Roche), Johnson & Johnson, Merck & Company, Pfizer, Takeda, and Teva; honoraria for consulting and stock options from Caldera Therapeutics, Mirador Therapeutics and SRT Therapeutics; and stock from Doximity.
Geert D’Haens has served as advisor and/or speaker for Abbvie, Abivax, Agomab, Alimentiv, Anaptys Bio, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Galapagos, Glaxo Smith Kline, Index Pharmaceuticals, Johnson and Johnson, Merck, Polpharm, Prometheus biosciences, Sanofi, Takeda, Tillotts.
Omoniyi J. Adedokun, Tae Eun Yang, Nat A. Terry, Rian Van Rampelbergh, and Marion L. Vetter are employees of Johnson & Johnson and may own stock or stock options.
David T Rubin reports consulting and/or speaker fees and/or advisory board participation for AbbVie, Altrubio, Apex, Avalo, Bristol Myers Squibb, Buhlmann Diagnostics, Celgene, Connect BioPharma, Intouch Group, Iterative Health, Johnson & Johnson, Lilly, Pfizer, Samsung Neurologica, and Takeda; Altrubio, Datos Health, and Iterative Health stock options; grants from Takeda; and membership on the Board of Directors of Cornerstones Health, Inc and on the Crohn’s & Colitis Foundation’s Board of Trustees.
Tadakazu Hisamatsu reports potential conflicts of interest with AbbVie, Bristol Myers Squibb, Daiichi-Sankyo, EA Pharma Co, Ltd., Eli Lilly, Gilead Sciences, Johnson & Johnson, JIMRO, Kissei Pharmaceutical Co, Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., and Takeda Pharmaceutical Co., Ltd.
Remo Panaccione reports potential conflicts of interest with Abbivax, Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, JAMP Bio, Johnson & Johnson, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, and UCB.
Silvio Danese reports potential conflicts of interest with AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity, Takeda, TiGenix, UCB, and Vifor.